AOC Praises Psychedelics 'Promise' as NDAA Reforms Advance

August 16, 2026

Photo by 10302144 via Pixabay.

Introduction

The amendment attached to the National Defense Authorization Act doesn't create a new psychedelics program from scratch. It takes an existing Department of Defense research initiative and stretches its timeline dramatically, from three years to nine. That simple swap, moving the authorization out to September 30, 2033, triples the runway lawmakers are giving the Pentagon to generate usable data on compounds like psilocybin and MDMA for treating PTSD and treatment-resistant depression in veterans and active-duty service members. The $10 million already allocated for military-focused psychedelic studies stays the same, but the longer horizon means researchers can run multi-phase trials, follow participants over time, and publish findings that hold up to scrutiny rather than rushing conclusions before a funding cliff. The provision is riding inside the House-passed version of the NDAA for Fiscal Year 2027, and it represents the latest chapter in a long push by Representative Alexandria Ocasio-Cortez, who has been filing or co-sponsoring psilocybin-related measures since her first term. The politics around psychedelics have shifted considerably since her 2019 amendment failed 91-331, and the current momentum owes something to President Trump's April 2026 executive order encouraging federal research into ibogaine and other compounds, along with $50 million in new funding for federal-state collaboration. But passing the House is the easy part, and the real test will come in conference committee, where the Senate's version of the NDAA, which has not signaled comparable psychedelics language, will need to be reconciled with the House's provisions.

What the New NDAA Amendments Actually Do

Photo by RDNE Stock project via Pexels.

The mechanics here are simple, even if the politics around them aren't. The amendment attached to the NDAA doesn't create a new psychedelics program from scratch -- it takes an existing one and stretches its timeline dramatically. Where current statute authorized a Department of Defense psychedelics research initiative to run for three years, the amended language swaps that out for nine years. That's not a minor tweak; it triples the runway lawmakers are giving the Pentagon to actually generate usable data.

Practically, that means DOD is now required to extend performance of the research it's already funding through September 30, 2033. That date matters because it moves the program well past the typical churn of congressional attention spans and administration turnover. Research on compounds like psilocybin and MDMA, especially when it involves clinical protocols with veterans dealing with PTSD or treatment-resistant depression, doesn't produce clean answers on a one- or two-year cycle. A nine-year window gives investigators room to run multi-phase trials, follow up with participants over time, and publish findings that can actually hold up to scrutiny rather than getting rushed out before a funding cliff.

Money-wise, the underlying legislation had already set aside $10 million specifically for military-focused psychedelic studies. This amendment doesn't add new dollars to that pot -- it's about time horizon, not budget size. So the practical effect is that whatever gets funded under that $10 million allocation now has a much longer leash to actually finish the work, rather than scrambling to wrap up before the original three-year authorization expired.

All of this is riding inside the House-passed version of the NDAA for Fiscal Year 2027, which is itself just one stop in a long legislative process -- the Senate still has to weigh in before anything gets reconciled into a final bill. Worth noting too: the House Armed Services Committee's earlier draft language had already pushed DOD leadership to start tracking lawful pathways servicemembers could use to access psychedelic treatments, a sign this isn't purely about lab research anymore but about real-world clinical access for people in uniform.

AOC's Long Push for Psilocybin Research in the Military

Photo by Tahir Xəlfəquliyev via Pexels.

Ocasio-Cortez has been making this argument to anyone who'll listen for years, and she made it again to Marijuana Moment: psilocybin is one of the only compounds showing real, early clinical promise for treatment-resistant PTSD, the kind that doesn't respond to SSRIs, talk therapy, or the standard VA protocol. She's careful to frame this as a research question rather than a foregone conclusion, but her point is that veterans dealing with the worst cases have often already tried everything the current system offers and gotten nowhere.

That's the constituency she keeps coming back to. Veterans with treatment-resistant PTSD aren't a hypothetical population for a member who represents parts of the Bronx and Queens — they're people who show up at town halls describing years of failed medications and therapy that didn't stick. Ocasio-Cortez has argued that when someone has exhausted every conventional option and is still suffering, denying them access to a substance with promising trial data isn't caution, it's just neglect dressed up as caution.

This isn't a one-off talking point for her. Going back to her first term, Ocasio-Cortez has filed or co-sponsored psilocybin-related measures almost every session, ranging from bills expanding research access to riders attached to the National Defense Authorization Act aimed at loosening federal scheduling barriers for studying the compound. The through-line has been consistent even as the vehicles changed.

Her first major floor test came in 2019, when an amendment tied to psilocybin research access failed 91-331 — a lopsided loss that reflected how little appetite existed at the time for touching anything psychedelic-adjacent on the House floor. She tried again in 2021 with a similarly structured amendment, and while the numbers improved to 140-285, it still went down decisively.

The 2022 push looked different. Rather than a straightforward descheduling amendment, Ocasio-Cortez led an NDAA provision specifically directing the Department of Defense to study psilocybin and MDMA as therapeutic options for active-duty service members, tying the research mandate directly to military mental health rather than broader drug policy reform. That framing — treatment access for troops, not blanket legalization — has proven to be the more durable strategy of the two.

How Trump's Executive Order Set the Stage

Photo by rosanna17 via Pixabay.

The current momentum in Congress didn't happen in a vacuum. On April 18, 2026, President Trump signed Executive Order 14401, a directive that formally encouraged federal research into psychedelic compounds, with a particular emphasis on ibogaine, for treating mental health conditions like PTSD, treatment-resistant depression, and substance use disorder. Ibogaine has spent decades as a fringe treatment, popular in underground clinics and overseas retreats but largely locked out of mainstream U.S. research because of its Schedule I status. The order signaled the White House wanted that dynamic to change, and quickly.

The text of EO 14401 does more than express enthusiasm. It directs the FDA to prioritize its review of psychedelic compounds moving through the regulatory pipeline, and it instructs the DEA to look at loosening research restrictions that have historically made it slow and expensive for scientists to even obtain Schedule I substances for clinical trials. That second piece matters as much as the first: researchers have long complained that DEA registration requirements, security protocols, and import/export rules add months or years to studies that already face steep scientific hurdles.

The order also puts real money behind the rhetoric, allocating $50 million for federal-state collaboration on psychedelics research. That funding structure is notable because it opens the door for states that have already moved on psilocybin or ibogaine, Oregon and Colorado being the obvious examples, to plug their existing regulatory frameworks into a federal research effort rather than operating in isolation.

FDA Commissioner Marty Makary put a specific timeline on the ambition, telling reporters that national priority vouchers could let as many as three psychedelic compounds move through review in a matter of weeks rather than the years such applications typically take.

None of this arrived in isolation, either. It came four months after Trump's December 2025 executive order aiming to reschedule cannabis, an order that, as of April 2026, still hadn't been implemented, prompting Rep. Steve Cohen to publicly press the administration for answers on the delay.

What Happens Next: The Senate and Conference Wildcard

Photo by Aaron Johnson via Pexels.

Passing the House is the easy part. Every year the National Defense Authorization Act clears the lower chamber loaded with amendments that never see daylight again, and there's no guarantee the psychedelics provisions avoid that fate. The Senate is running its own version of the NDAA on a separate track, and as of now, senators haven't signaled whether they'll include comparable language extending the Department of Defense's psychedelics research authority or codifying the executive order Biden-era officials used to expand access to studies on MDMA, psilocybin, and other compounds for active-duty service members and veterans.

That mismatch matters because defense authorization bills don't become law until a conference committee — a small group of House and Senate negotiators — reconciles the two chambers' versions into a single text. This is where a lot of good policy goes to die, or at least gets trimmed down to something unrecognizable. Riders on drug policy, criminal justice, and health research have a long history of getting stripped in conference, especially when leadership wants a clean bill that won't attract controversy or delay final passage. The NDAA is considered must-pass legislation, and that status makes it a magnet for horse-trading nobody sees until the final text drops.

The good news for advocates is that psychedelics research for veterans has built genuinely bipartisan support in recent years, with lawmakers from both parties citing PTSD and suicide rates among former service members as justification. That doesn't guarantee survival through conference, but it does mean the provision isn't an obvious target for a party-line strike. Groups tracking the bill say the real test will be whether the research extension and the executive order language emerge intact, watered down, or gone entirely once negotiators finish their closed-door sessions, likely in the final months of the year.

Timing adds pressure on top of that uncertainty. The current three-year window authorizing this research is set to expire, and without a clean extension, ongoing studies risk losing their legal footing right as researchers are producing early data. Anyone following this fight should expect the real answer to come only after conference negotiators finish their work, not before.

Conclusion

The nine-year extension for DOD psychedelics research is a significant step forward, but it is not the finish line. The NDAA still has to survive conference committee, where riders on drug policy and health research have a long history of getting stripped or watered down, especially when leadership wants a clean bill that won't attract controversy. The good news for advocates is that psychedelics research for veterans has built genuinely bipartisan support in recent years, with lawmakers from both parties citing PTSD and suicide rates among former service members as justification. That does not guarantee survival through conference, but it does mean the provision is not an obvious target for a party-line strike. The current three-year window authorizing this research is set to expire, and without a clean extension, ongoing studies risk losing their legal footing right as researchers are producing early data. The executive order from April 2026, with its $50 million funding allocation and directive to the FDA and DEA to prioritize psychedelic research, adds administrative momentum that exists independently of whatever Congress ultimately does with the NDAA. But the order alone cannot authorize DOD to keep running trials beyond what statute allows, which is why the legislative extension matters. For veterans and active-duty service members who have exhausted conventional treatments and are still suffering, the stakes are real. A nine-year research window is not the same as clinical access, but it is a necessary precondition for getting there. The real answer on whether this research continues uninterrupted will come only after conference negotiators finish their closed-door sessions, likely in the final months of the year, and anyone following this fight should expect the outcome to be decided in that room rather than on any floor vote.